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Abstract Glutaminyl cyclase (QC) was discovered
recently as the enzyme catalyzing the pyroglutamate (pGlu
or pE) modiﬁcation of N-terminally truncated Alzheimer’s
disease (AD) Ab peptides in vivo. This modiﬁcation confers
resistance to proteolysis, rapid aggregation and neurotox-
icity and can be prevented by QC inhibitors in vitro and in
vivo, as shown in transgenic animal models. However, in
mouse brain QC is only expressed by a relatively low
proportion of neurons in most neocortical and hippocampal
subregions. Here, we demonstrate that QC is highly abun-
dant in subcortical brain nuclei severely affected in AD. In
particular, QC is expressed by virtually all urocortin-1-
positive, but not by cholinergic neurons of the Edinger–
Westphal nucleus, by noradrenergic locus coeruleus and by
cholinergic nucleus basalis magnocellularis neurons in
mouse brain. In human brain, QC is expressed by both,
urocortin-1 and cholinergic Edinger–Westphal neurons and
by locus coeruleus and nucleus basalis Meynert neurons.
In brains from AD patients, these neuronal populations
displayed intraneuronal pE-Ab immunoreactivity and
morphological signs of degeneration as well as extracellular
pE-Ab deposits. Adjacent AD brain structures lacking QC
expression and brains from control subjects were devoid of
such aggregates. This is the ﬁrst demonstration of QC
expression and pE-Ab formation in subcortical brain
regions affected in AD. Our results may explain the high
vulnerability of deﬁned subcortical neuronal populations
and their central target areas in AD as a consequence of QC
expression and pE-Ab formation.
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The appearance of neuroﬁbrillary tangles, loss of speciﬁc
neuronal populations and deposits of Ab peptides in neo-
cortical brain structures are major histopathological
hallmarks of Alzheimer’s disease (AD) [60]. Ab peptides
are liberated from the amyloid precursor protein (APP)
after sequential enzymatic action of b- and c-secretases.
The c-secretase cleavage results in the generation of
Ab1–40 and Ab1–42 peptides, which exhibit different
potencies of aggregation, ﬁbril formation and neurotoxicity
[17, 23, 24, 44, 62]. Additionally, N-terminally truncated
Ab peptides displaying an N-terminal glutamate residue
are abundant in brains from AD patients [29, 46, 51, 61,
64]. A substantial proportion of these N-truncated Ab
peptides undergoes subsequent cyclization of N-terminal
glutamate (E) into pyroglutamate (pE) [50, 51]. The
resulting pE-Ab peptides have been shown to be a major
constituent of Ab deposits in sporadic and familial AD
[38, 43, 50, 73]. Thus, the assumption has been made that
pE-Ab peptides could play a prominent role in AD
pathogenesis.
This view is supported by a number of experimental
observations. For example, a particular neurotoxicity of
pE-Ab peptides in primary neurons, neuronal cell lines
and transgenic animals has been demonstrated [1, 47, 72].
Moreover, pE-modiﬁcation of N-truncated Ab peptides is
believed to have a signiﬁcant inﬂuence on plaque gener-
ation and clearance. So it has been shown that the
cyclization of glutamate into pE leads to a loss of
N-terminal charge resulting in accelerated aggregation of
pE-Ab when compared with unmodiﬁed Ab peptides [19,
47] and that pE-Ab acts as a seed for aggregation as well
as for co-aggregation of non-modiﬁed Ab peptides [12,
36, 53, 56]. Furthermore, cyclization of N-terminal glu-
tamate of Ab peptides confers resistance to degradation
by most aminopeptidases as well as Ab-degrading endo-
peptidases [49].
However, for a long time, the molecular pathway lead-
ing to N-terminal glutamate cyclization of truncated Ab
peptides remained elusive. Recently, glutaminyl cyclase
(QC) has been shown to be the enzyme catalyzing pE-Ab
peptide generation in vitro [52] and in vivo [11, 54, 55].
Chronic inhibition of QC in transgenic mouse models of
AD resulted in reduced pE-Ab peptide generation and in
diminished total Ab peptide concentrations [54]. Thus, the
enzymatic activity of QC appears to be a prerequisite for
pE-Ab peptide generation and, therefore, QC-expressing
neurons may be at special risk for degeneration. In a recent
study focussing on QC expression in telencephalic and
diencephalic mouse brain regions, we observed QC in a
subpopulation of lateral and paraventricular hypothalamic
neurons and in a moderate number of GABAergic inter-
neurons in the hippocampal molecular layer, in the hilus of
the dentate gyrus and in all layers of the neocortex [18].
However, the proportion of QC neurons in cortex and
hippocampus displaying pronounced immunoreactivity
was rather low (0.5–2%), which may explain the lack of
substantial neurodegeneration in these brain structures in
APP transgenic mouse models. On the other hand, even the
degeneration of a small number of GABAergic interneu-
rons in the hippocampus may have perturbing effects on
long-term potentiation and on the performance in learning/
memory tests [66].
In AD, in addition to neocortical and hippocampal
neurodegeneration and Ab plaque pathology, there is a
selective loss of deﬁned neuronal populations in distinct
subcortical brain nuclei, including the nucleus basalis
Meynert (NbM) of the cholinergic basal forebrain [2, 9,
70], the Edinger–Westphal nucleus (EWN) [21, 45, 58, 59]
and the locus coeruleus (LC) [5, 6, 16, 32, 67]. Therefore,
we asked whether QC may be expressed by neurons of
these nuclei and, if so, whether it may contribute to pE-Ab
pathology.
Materials and methods
Experimental animals
Wild type C57Bl6 mice and QC knock-out mice aged
2–3 months (N = 4 each) were used for the immunohis-
tochemical analysis of QC expression in EWN, LC and
Nbm. QC knock-out mice were generated on the basis of a
classical homologous recombination approach. Cre-medi-
ated excision of exons 5 and 6 was conﬁrmed by PCR and
RT-PCR. The constitutive deletion of these exons resulted
in an additional frame shift and thus in a complete loss of
the C-terminal part of the protein (not shown).
Preparation of mouse brain samples
for immunohistochemistry
Mice were anaesthetised with pentobarbital and perfused
transcardially with 25 ml phosphate-buffered saline (PBS
0.01 M, pH 7.4) followed by perfusion with 25 ml 4%
paraformaldehyde in phosphate buffer (PB 0.1 M, pH
7.4). The brains were removed from the skull and
postﬁxed by immersion in the same ﬁxative overnight at
4C. After cryoprotection in 30% sucrose in 0.1 M PB
for 3 days, the brains were snap-frozen in n-hexane at
-68C and stored at -20C. Coronal sections (30 lm)
were cut on a sliding microtome and collected in
0.1 M PB.
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Tissue preparation
Fifteen mm-thick tissue blocks were prepared in the frontal
plane according to the atlas of the human brain [31] and
ﬁxed in 4% paraformaldehyde for 3–4 days. Areas con-
taining the regions of interest were cryoprotected in 30%
sucrose in 0.1 M PBS, pH 7.4. Series of 30 lm-thick
sections were cut on a freezing microtome and collected in
PBS containing 0.1% sodium azide.
Identiﬁcation of anatomical regions and applied
nomenclature
Anatomical regions were identiﬁed using Nissl-stained
sections and the atlas of the human brain [31]. The
nomenclature of brain regions was mainly adopted from
atlases of human brain [31], human brainstem [42] and
rhesus monkey brain [41]. We additionally used the data of
detailed anatomical descriptions of the EWN [21, 22], the
LC [33, 34] and the NbM [2].
Characterization of human brain tissue
The EWN, LC and NbM were evaluated for QC expression
and for pE-Ab deposition in brains from eight AD cases
and from eight age-matched control subjects (Table 1). The
deﬁnite diagnosis of AD for all cases used in this study was
based on the presence of neuroﬁbrillary tangles and neu-
ritic plaques in the hippocampal formation and neocortical
areas and met the criteria of the National Institute of
Neurologic and Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related Disorders Association
[37]. Brain tissue containing the EWN (Talairach space
28–29 mm) according to [31], the LC (Obex 20–32)
according to [42] and the NbM (Ch4; Talairach space -2
to -0.6 mm) according to [2, 31] from the same cases was
used for immunohistochemistry to detect the presence of
QC, pE-Ab and neuronal markers. Case recruitment and
autopsy were performed in accordance with guidelines set
by the Ethical Committees of the University of British
Columbia and the Leipzig University (License# 063/2000).
The required consent was obtained for all cases.
Immunohistochemistry for QC, Ucn-1, ChAT, TH
and pE-Ab
All immunohistochemical procedures were performed on
free-ﬂoating brain sections. Immunohistochemistry in
human brain to detect QC was performed using the rabbit
antiserum 1301 (1:500), which was raised against recom-
binant full length mouse QC expressed in yeast.
The polyclonal antiserum was puriﬁed using a HiTrap
rProtein A FF prepacked column (5 ml, GE Healthcare)
and antibody elution by a shift to pH 3 using a citric acid
buffer. The neutralised protein solution was stored at
-20C after addition of 50% glycerol. The antibody
showed no signiﬁcant differences in detecting mouse, rat
and human QC in western blot analysis and immunohis-
tochemistry, which appears conceivable considering a 85%
protein sequence identity. Moreover, the speciﬁcity of the
QC antiserum was previously shown by the robust labelling
of mouse hypothalamic neurons, a known source of QC
and of peptide hormones modiﬁed by QC, and by the
absence of this labelling in brains from QC knock-out mice
[18]. Additionally, the speciﬁcity of QC immunolabelling
was validated by similar staining patterns obtained using a
commercially available mouse anti-human QC antiserum
(Abnova 1:500). On consecutive human brain sections, the
neuronal markers urocortin-1 (Ucn-1), choline acetyl-
transferase (ChAT) and tyrosine hydroxylase (TH) as well
as pE-Ab were detected using the following antisera: goat
anti-Ucn-1 (St. Cruz 1:200), goat anti-ChAT (Millipore
1:500), mouse anti-TH (Millipore 1:500) and mouse anti-
pE-Ab (Synaptic Systems 1:200). All sections were pre-
treated with an initial antigen retrieval step by heating to
90C in 0.1 M citrate buffer, pH 2.5, for 3 min followed by
rinsing with PBS-T. Brain sections were further treated
with 60% methanol, 2% H2O2 for 1 h prior to incubation
with the primary antibodies at 4C overnight in a humid
chamber. The following day sections were incubated with
secondary biotinylated donkey anti-rabbit, donkey anti-
mouse or donkey anti-goat antibodies (Dianova 1:1,000)
for 60 min at room temperature followed by the ABC
method, which comprised incubation with complexed
streptavidin—biotinylated horseradish peroxidase. Incuba-
tions were separated by washing steps (3 times 5 min in
PBS-T). Binding of peroxidase was visualised by incuba-
tion with 2 mg 3,30-diaminobenzidine (DAB), 20 mg
nickel ammonium sulphate and 2.5 llH 2O2 per 5 ml Tris
buffer (0.05 M, pH 8.0) for 1–2 min. The enzymatic
reaction resulted in black labelling, which was well dis-
tinguishable from the brown neuropigment present in many
human LC neurons.
Immunohistochemistry in brains from wild type and QC
knock-out mice was performed similarly but developed by
incubation with 4 mg DAB and 2.5 llH 2O2 per 5 ml Tris
buffer (0.05 M, pH 7.6) for 1–2 min resulting in a brown
reaction product [18]. In control experiments, primary
antibodies were omitted, resulting in absence of staining.
Double immunoﬂuorescent labelling procedures
In order to relate QC expression in mouse brain to marker
proteins of deﬁned neuronal populations, double
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anti-QC antiserum 1301 (1:250) combined with goat anti-
Ucn-1 (1:100), goat anti-ChAT (1:250) and mouse anti-TH
(1:250), respectively. Brain sections were incubated with
cocktails of primary antibodies overnight at 4C. The fol-
lowing day, sections were washed three times with TBS
and were then incubated with appropriate cocktails of
secondary antibodies (i.e. biotinylated donkey or goat anti-
rabbit; 1:400 and Cy3-conjugated goat anti-mouse or
donkey anti-goat, 1:200 Dianova) for 60 min at room
temperature. After washing, brain sections were incubated
with streptavidin-Cy2 conjugates (Dianova 1:100) for
45 min, washed again and mounted onto gelatine-coated
slides. In double immunoﬂuorescent labellings, the omis-
sion of one primary antibody resulted in the depletion of
the corresponding ﬂuorescent signal without affecting the
detection of the second antigen.
Microscopy
Light microscopy
Tissue sections were examined with a Zeiss Axiovert
200 M microscope equipped with a motorised stage
(Ma ¨rzha ¨user, Germany) with MosaiX software and by
means of a CCD camera (Zeiss MRC) connected to an
Axiovision 4.6 image analysis system (Zeiss, Germany).
Confocal laser scanning microscopy
Laser scanning microscopy (LSM 510, Zeiss, Oberkochen,
Germany) was performed to reveal co-localization of QC
with TH, Ucn-1 and ChAT in LC, EWN and Nbm,
respectively. For Cy2-labelled QC (green ﬂuorescence), an
argon laser with 488 nm excitation was used and emission
from Cy2 was recorded at 510 nm applying a low-range
band pass (505–550 nm). For Cy3-labelled TH, Ucn-1 and
ChAT (red ﬂuorescence), a helium-neon laser with 543 nm
excitation was applied and emission from Cy3 at 570 nm
was detected applying high-range band pass (560–615 nm).
Photoshop CS2 (Adobe Systems, Mountain View, CA,
USA) was used to process the images obtained by light
and confocal laser scanning microscopy with minimal
alterations to brightness, sharpness, colour saturation and
contrast.
Quantiﬁcation of QC-immunoreactive neurons
and pE-Ab deposits
Quantitative analysis of ChAT-, Ucn-1-, TH- and QC-
immunoreactive neurons and pE-Ab deposits present in
EWN, LC and human NbM was performed following the
procedure described in [13]. Noradrenergic LC neurons in
stained sections were additionally identiﬁed by the content
of neuromelanin. Neurons were counted when the soma
Table 1 Human brain tissue
used for QC and pE-Ab
labellings
AD Alzheimer’s disease, PMD
postmortem delay, COD cause
of death, EC entorhinal cortex
Case # PMD
(h)
Gender Age
(years)
Brain
weight (g)
COD Braak
staging
Control
1 48 Female 75 1,130 Cardial infarction 0
2 72 Female 68 1,284 Bronchopneumonia 0
3 24 Female 82 1,180 Ovarian cancer 0
4 48 Male 78 1,420 Cardial infarction 0
5 9 Female 43 n.a. Drug overd. (insulin) 0
6 24 Female 80 1,190 Lung cancer 0
7 25 Female 75 1,234 Lung cancer 0
8 7 Male 78 1,394 Pulmonary failure 0
Mean 32.1 6/2 72.4
AD
1 55 Female 95 1,060 Cardial infarction VI
2 32 Female 70 1,200 Respiratory failure IV
3 28 Male 68 960 Bronchopneumonia VI
4 6 Female 58 1,010 Respiratory failure IV
5 16 Female 65 1,080 Respiratory failure V
6 40 Female 79 1,006 n.a. IV
7 24 Male 69 934 n.a. V
8 42 Female 91 1,230 Stroke IV
Mean 30.4 6/2 74.4
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EWN, LC and NbM and the location of neurons inside
these nuclei were assessed by means of a Stereoinvesti-
gator (Microbrightﬁeld, Williston, VT, USA; including a
Zeiss Axioskop 2 plus, Ma ¨rzha ¨user micropositioning sys-
tem and a Ludl 5000 controller) with the Neurolucida
software. QC expression in EWN, LC and NbM was
investigated in three sections from rostral to caudal (largely
comprising the whole nucleus) in all cases. In sections
analysed, the number of neurons labelled for the neuronal
marker (e.g. ChAT, TH or Ucn-1) in each brain region
of control brain was set to 100%. The relative numbers of
QC-immunoreactive neurons and pE-Ab deposits in brain
regions analysed was calculated using the formula of
Konigsmark [27].
Results
Distinct QC expression in the mouse EWN
First, QC immunohistochemistry was performed on mouse
coronal midbrain sections at the level of bregma -3.1 to
-3.8 mm. In the subcortical part of these sections, we only
observed modest QC immunoreactivity in a relatively low
percentage of neurons of some neuronal populations
including substantia nigra and ventral tegmental area (not
shown). In contrast, there was a small but robustly QC-
expressing assembly of neurons within the EWN (Fig. 1).
Labelling was absent from QC knock-out mouse brain
sections, demonstrating the speciﬁcity of the immunohis-
tochemical QC detection (Fig. 1). Since the EWN is known
to be composed of a preganglionic cholinergic portion and
a non-preganglionic, Ucn-1-positive part, we sought to
identify the neuronal subpopulation expressing QC in this
structure. Double immunoﬂuorescent labellings revealed
that QC is co-localised with Ucn-1 (Fig. 1) but not with
ChAT (not shown) in neurons of the mouse EWN. Thus,
QC-expressing neurons in the EWN represent the non-
preganglionic, Ucn-1-positive part of this nucleus in mouse
brain.
Distinct QC expression in the mouse locus coeruleus
In order to extend these ﬁndings and to substantiate a pos-
siblefunctionofQCinpE-Abgenerationinvivo,westudied
LC, a brainstem nucleus known to be severely affected in
AD. As in the case of the EWN, there was strong and spa-
tially deﬁned QC labelling of neurons in the LC region of
mouse brain (Fig. 2). This labelling was absent in brain
sections from QC knock-out mice (Fig. 2). In order to
clearly identify these neurons, immunoﬂuorescent double
labelling of QC and TH was performed. QC was found to be
strictly co-localised to TH, demonstrating co-expression by
mouse noradrenergic LC neurons (Fig. 2).
Distinct QC expression in the mouse nucleus basalis
magnocellularis
In contrast to the robust QC expression by almost all mouse
Ucn-1-positive EWN and TH-positive LC neurons, the
mouse Nbm contained relatively few QC-immunoreactive
neurons (Fig. 3). Double labelling with the cholinergic
marker enzyme ChAT in this brain region revealed that
approximately 50% of mouse Nbm cholinergic neurons co-
expressed QC (Fig. 3).
It is important to note that in brains from QC knock-out
mice, the neuronal marker proteins Ucn-1, TH and ChAT
were detected in EWN, LC and Nbm neurons, respectively.
This indicates survival of these neuronal populations in the
absence of QC expression.
Distinct QC expression in human EWN, LC and NbM
We then asked whether QC is also expressed in the cor-
responding subcortical nuclei of human brain and whether
pE-Ab formation spatially correlates with QC expression
in AD brains. Immunohistochemical labelling of human
midbrain sections cut at the level of the EWN revealed a
distinct and robust QC expression in this brain structure
(Fig. 4), conﬁrming observations made in mouse brain. In
adjacent brain sections, two marker proteins of neuronal
subpopulations of the EWN—Ucn-1 and ChAT—were
visualised. In contrast to the mouse brain, the cholinergic
part of this nucleus was much larger in relative size in
human brain and contained more neurons when compared
with the Ucn-1-positive portion (Fig. 4). Interestingly, QC
expression was not limited to the Ucn-1-positive portion of
the human EWN, but was also present in the cholinergic
part of this brain structure (Fig. 4). This ﬁnding differs
from the observations made in mice, where QC expression
in the EWN was restricted to Ucn-1-positive neurons.
Neurons in adjacent brain structures outside the EWN and
perioculomotor area, such as red nucleus and superior
colliculus did not display QC immunoreactivity.
Since we observed QC expression in mouse LC and
because of the well-documented LC pathology in AD, we
also examined human brainstem sections containing this
structure. In similarity to observations made in mouse
brain, QC was also found to be expressed by noradrenergic
neurons in human LC (Fig. 4). The identity of QC-immu-
noreactive neurons as noradrenergic LC neurons was
demonstrated by the typical neuronal pigment and by the
expression of TH in consecutive brain sections. Interest-
ingly, QC immunoreactivity was not limited to LC
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123Fig. 1 QC expression in mouse
Edinger–Westphal nucleus. Top
row QC immunoreactivity is
absent from midbrain sections
of QC knock-out mice as shown
at increasing magniﬁcations
from left to right. In contrast,
there is a speciﬁc and robust
labelling of a neuronal
population in the EWN of wild
type mice (middle row). Since
the EWN is known to contain
both, Ucn-1 and ChAT neurons,
double labellings were
performed. QC (green
ﬂuorescence) was found to be
co-localised with Ucn-1 (red
ﬂuorescence; bottom row), but
not with ChAT (not shown)
Fig. 2 QC expression in mouse
locus coeruleus. Top row QC
immunoreactivity is absent from
brainstem sections of QC
knock-out mice as shown at
increasing magniﬁcations from
left to right. In contrast, there is
a speciﬁc and robust QC
labelling of a neuronal
population corresponding to the
LC of wild type mice (middle
row). In order to identify these
neurons as noradrenergic LC
neurons, double labellings were
performed. There was an almost
complete overlap of QC (green)
and TH (red) immunoreactivity
in the mouse LC (bottom row)
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123neuronal somata but was also detected in TH-positive
ﬁbres.
Although only a sub-population of cholinergic Nbm
neurons in mouse brain contained QC, the analysis of
human brain sections revealed strong QC expression by
virtually all NbM neurons (Fig. 4). The intracellular pat-
tern of QC immunoreactivity in the neuronal somata and
processes was similar to that detected in EWN and LC.
Intraneuronal and extracellular pE-Ab aggregates
in the Alzheimer’s disease EWN, LC
and NbM
Given the high level of QC expression in human EWN, LC
and NbM and the role of QC in pE-Ab formation, we asked
whether there is pE-Ab plaque pathology in these human
brain nuclei from AD patients. Using a mouse monoclonal
antibody raised against pE-Ab, we observed focal plaque
formation in both, the Ucn-1-positive and the cholinergic
portion of EWN as well as in LC and NbM of AD brain
(Fig. 5). Similar to the QC staining pattern, brain structures
outside the EWN and perioculomotor area, such as red
nucleus and superior colliculus did not display pE-Ab
immunoreactivity. Additionally, we detected intraneuronal
accumulation of pE-Ab in EWN, LC and NbM neurons in
brain tissue from AD patients but only rarely in normal
brain (Fig. 5).
Quantitative analysis of QC expression and pE-Ab
deposit formation
In order to obtain quantitative data on the degree of QC
expression and pE-Ab deposit formation in the subcortical
nuclei analysed, the numbers of Ucn-1 and cholinergic
EWN, TH-positive LC and cholinergic NbM neurons were
determined and the proportion of QC-positive neurons was
calculated for each structure. In the normal human brain,
almost all NbM neurons and approximately 80% of LC
neurons co-expressed QC, whereas in the EWN only 20%
of neurons were found to be QC immunoreactive (Fig. 6).
In brains from AD patients, neuronal numbers were
reduced by 39, 26 and 12% in NbM, LC and the Ucn-1 and
cholinergic part of EWN, respectively (Fig. 6). Thus, the
highest degree of neuronal loss was detected in the brain
region with the most abundant QC expression. Addition-
ally, a signiﬁcant number of pE-Ab deposits was detected
in NbM, LC and EWN from AD patients but not from
control subjects (Fig. 6). As in the case of neuronal loss,
the most pronounced pE-Ab deposit formation was
observed in NbM of AD subjects.
Fig. 3 QC expression in mouse
nucleus basalis magnocellularis.
Top row QC immunoreactivity
is absent from basal forebrain
sections of QC knock-out mice
as shown at increasing
magniﬁcations from left to
right. In contrast, there is a
speciﬁc QC labelling of a
neuronal population
corresponding to the nucleus
basalis of wild type mice
(middle row). In order to
identify these neurons as
cholinergic basal forebrain
neurons, double labellings were
performed. QC (green) was
found to be co-expressed by a
proportion of ChAT-
immunoreactive (red) neurons
in the mouse nucleus basalis
(bottom row). Double-labelled
neurons are indicated by yellow
colour in the overlay channel
and by arrows
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The aim of this study was to reveal whether QC expression
and pE-Ab deposition can be spatially correlated with
deﬁned neuronal populations known to be affected by
selective degeneration and by Ab pathology in AD brains.
For the initial screening of QC expression in the basal
forebrain and brainstem, mice were used because of
unrestricted access and the availability of QC knock-out
mice as controls for the immunohistochemical QC
labelling.
First, we demonstrated distinct QC expression by Ucn-
1-positive EWN neurons in mice. Ucn-1 is a neuropeptide
of the corticotropin-releasing factor (CRF) family and
binds to CRF receptors 1 and 2, to the latter with higher
afﬁnity than CRF itself [65]. Ucn-1 is known to play a role
in the regulation of food intake [63], energy balance [10]
and anxiety [39] and Ucn-1 neurons of the EWN in par-
ticular appear to be involved in stress response [15, 28, 69]
and alcohol consumption [3]. Interestingly, in a number of
publications, midbrain structures including the EWN have
been reported to display Ab and Tau histopathology in AD
patients [21, 45, 58, 59]. However, a comparison of these
histological data appears difﬁcult since the term EWN
comprises several functionally different cell groups (pre-
ganglionic and several non-preganglionic cell groups, the
latter including Ucn-1 positive neurons) and attempts have
only been made recently to provide a clear and well-
deﬁned nomenclature of the EWN in mouse [68] and
human brain [21, 22, 48].
With regard to QC expression in the EWN complex, we
observed remarkable differences between mouse and
human brain. Most strikingly, QC expression was limited
to Ucn-1-positive EWN neurons in mice but also present in
preganglionic cholinergic EWN neurons in humans. The
Fig. 5 pE-Ab aggregates in human AD Edinger–Westphal nucleus,
locus coeruleus and nucleus basalis Meynert. Left In the EWN of
control subjects there was only a faint intraneuronal pE-Ab immu-
noreactivity. In contrast, in brains from AD patients the EWN was
robustly labelled with intraneuronal pE-Ab (arrows) and pE-Ab
plaques (asterisks). Middle In the LC of control subjects numerous
neurons containing neuropigment (brown) but rarely intraneuronal
pE-Ab accumulations (arrow) and no pE-Ab deposits were present. In
brains from AD patients there were intraneuronal pE-Ab accumula-
tions (arrows) and pE-Ab immunoreactive plaques (asterisks). Right
Intraneuronal pE-Ab (arrows) and pE-Ab deposits (asterisks) were
detected in the NbM of AD patients but not in this brain region of
control subjects. Scale bars in top row 600 lm, in bottom row 50 lm
Fig. 4 QC expression in the human Edinger–Westphal nucleus, locus
coeruleus and nucleus basalis Meynert. QC immunoreactivity was
present in midbrain sections in a deﬁned cell group (top left). These
cells include both Ucn-1 and ChAT expressing subpopulations of the
Edinger–Westphal nucleus as shown by the labelling of these marker
proteins in adjacent brain sections. QC-immunoreactive neurons were
also detected in brainstem sections in a small, deﬁned cell group
within the locus coeruleus area (middle left). Labelling of consecutive
brain sections with TH identiﬁed these neurons as noradrenergic LC
neurons (middle right). The highest density of QC-immunoreactive
neurons was detected in the nucleus basalis Meynert (bottom left),
which was identiﬁed by the presence of cholinergic Ch4 neurons
(bottom right). Scale bars in overview 500 lm, in higher magniﬁca-
tion inserts 100 lm, 150 lm and 200 lm as indicated
b
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123latter neuronal population has a function in adaptive
pupillary reaction, which has been reported to be affected
in AD patients in response to treatment with cholinergic
antagonists [57]. Our demonstration of QC expression, pE-
Ab formation and neurodegeneration in both Ucn-1 and
cholinergic portions of EWN is in agreement with neuro-
pathology in this nucleus observed earlier [45, 58, 59].
In addition to the EWN, we also demonstrated robust QC
expression by a high proportion of noradrenergic LC neu-
rons in mouse and human brain. LC degeneration is an early
feature of AD pathology [14, 32]. The well-described nor-
adrenergicneuronalloss[16]isaccompaniedbyAbandTau
pathology and correlates with Ab plaque load, neuroﬁbril-
lary tangle formation and the severity of dementia [5, 6, 67,
71]. However, since LC neurons are known to provide
essential noradrenergic innervation to the hippocampal
formation and neocortex [30], it is conceivable that sec-
ondary morphological and neurochemical changes also
occur in these target regions. Indeed, elevated hippocampal
acetylcholine and serotonin release as observed in mild
cognitive impairment patients was also detected after spe-
ciﬁc lesions of noradrenergic LC neurons in experimental
animals [25]. Moreover, noradrenaline deﬁciency has been
shown to promote neocortical and hippocampal Ab pathol-
ogy in transgenic animal models [20, 26]. Additionally,
there is evidence for the seeding of neuritic Ab plaques in
target regions of brainstem neurons in AD [40].
This is also supported by the robust QC expression in
human cholinergic NbM neurons. Interestingly, QC
expression in the corresponding nucleus of mouse brain
was less pronounced, a ﬁnding which might point towards
a higher physiological relevance of QC expression in
human NbM when compared with mouse Nbm neurons. In
AD, the degeneration of cholinergic NbM neurons is an
early and consistent pathological feature and results in
cholinergic denervation of the cortical mantle [2, 9, 70].
This neocortical cholinergic hypoactivity has been corre-
lated to the degree of dementia and is targeted by
cholinomimetic approaches in order to at least temporarily
attenuate cognitive decline in AD patients [44]. As in the
case of noradrenergic LC neurons, cholinergic NbM neu-
rons innervate brain regions severely affected by Ab
pathology and anterograde transport of QC and/or pE-Ab
may contribute to neocortical Ab deposition. We thus
believe that QC expression and subsequent pE-Ab forma-
tion may play a causative role in the speciﬁc deterioration
of cholinergic NbM and noradrenergic LC neurons and,
subsequently, in the alteration of neocortical and hippo-
campal function and in the seeding of neuritic plaques in
AD.
In all human brain regions with high QC expression
studied here, we detected intraneuronal pE-Ab and pE-Ab
plaques in the brains from AD patients. The monoclonal
pE-Ab antibody used in this study has been thoroughly
characterised recently and was shown to detect pE-Ab
aggregates in neocortical brain tissue from sporadic and
familial AD cases [73]. The pE-Ab plaque load in NbM,
LC and EWN was comparable to that reported for total Ab
deposits in these structures [2, 5, 45] and indicates that
most, if not all, of these Ab plaques contain pE-modiﬁed
Ab peptides. Interestingly, the proportion of QC-immu-
noreactive neurons and numbers of pE-Ab deposits were
highest in NbM, which also displayed the most profound
neuronal loss in AD. In addition to the local formation of
pE-Ab aggregates at sites of QC-immunoreactive somata,
pE-Ab peptides may be released in target areas of projec-
tion neurons and may form Ab plaques in brain regions
devoid of QC and/or APP expression. Such a phenomenon
was recently demonstrated in APP/PS1 knock-in mice with
neocortical and hippocampal, but not thalamical, transgene
expression [8]. The authors ﬁrst observed intraneuronal Ab
in cortical neurons at 2 months of age, followed by
extracellular cortical Ab deposits at 6 months of age. In
the thalamus of these mice, where no transgenic APP
is expressed, extracellular Ab deposits were detected at
6 months of age without preceding intracellular Ab
appearance. The authors concluded that Ab may be
deposited in brain regions where it is not produced via
axonal transport and secretion from nerve terminals. Thus,
in their animal model Ab is produced in neocortex and
Fig. 6 Quantiﬁcation of QC-expressing neurons and pE-Ab deposits
in normal human brain and in AD. The highest proportion of QC-
immunoreactive neurons in control subjects was detected in the NbM,
followed by LC and EWN. In all brain regions analysed, there was a
reduction of the neuronal number in AD as identiﬁed by expression of
Ucn-1/ChAT, TH and ChAT, respectively (* p\0.05). While in
control subjects no pE-Ab deposits were detected in any of the brain
nuclei investigated, a signiﬁcant number of pE-Ab deposits was
detected in AD brains. Both, neuronal loss and formation of pE-Ab
deposits was most pronounced in NbM
204 Acta Neuropathol (2010) 120:195–207
123released from corticothalamic ﬁbres in thalamus. In simi-
larity to this scenario, our data suggest that pE-Ab
generated by EWN, LC and NbM neurons may be released
at neocortical and hippocampal target regions.
Taken together, the demonstration of robust and spa-
tially restricted QC expression and pE-Ab formation in the
EWN, LC and NbM provides further evidence for pE-Ab
formation by QC in vivo. Since pE-Ab confers exceptional
neurotoxicity [1, 47] and since intraneuronal pE-Ab gen-
eration has been linked to neurodegeneration in animal
models of AD [7, 72], QC-expressing EWN, LC and NbM
neurons appear to be at high risk. Indeed, these neuronal
populations are affected in AD and some clinical charac-
teristics of AD patients such as dementia, anxiety,
depression, compromised stress response and attention
deﬁcits [4, 9, 21, 35] could be—at least partially—attrib-
uted to compromised function of EWN, LC and NbM
neurons. Moreover, in control subjects QC is expressed in
all subcortical nuclei investigated without accompanying
pE-Ab deposit formation. This indicates a yet unidentiﬁed
physiological function for QC outside the hypothalamus,
which does not normally lead to pE-Ab deposition or to
neurodegeneration. In AD, however, there is pE-Ab for-
mation and neurodegeneration in LC, EWN and NbM.
Thus, it appears that QC expression alone is not sufﬁcient
for pE-Ab formation and neurotoxicity, but a dysbalance in
the expression of APP, its processing by b- and c-secre-
tases and N-terminal Ab truncation have to occur to
generate the pathogenic QC substrate. In conclusion, we
postulate that among multiple mechanisms contributing to
the pathogenesis of AD, QC plays an important role in
EWN, LC and NbM neurodegeneration and in pE-Ab
plaque pathology, both locally and in the cortical and
hippocampal target regions of these projection neurons. As
a consequence, pharmacological QC inhibition should
reduce pE-Ab production and exert beneﬁcial effects on
these neuronal populations.
Acknowledgments We thank R. Jendrek (Paul Flechsig Institute for
Brain Research), H. Cynis, K. Schulz, M. Bornack, E. Scheel and M.
Buchholz (Probiodrug) and S. Yu (Kinsmen Laboratory of Neuro-
logical Research) for technical assistance. This work was supported
by the German Federal Department of Education, Science and
Technology, BMBF grant #3013185 to HUD. Aspects of this work
were also supported by the Paciﬁc Alzheimer Research Foundation to
CS and PLM and by the 7th Framework Program Health of the
European Commission (Neuropro, Grant Agreement #223077) to SR.
MM is member of the Graduiertenkolleg GRK 1097 funded by the
German Research Foundation and of the MD/PhD program at the
University of Leipzig.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Acero G, Manutcharian K, Vasilevko V et al (2009) Immuno-
dominant epitope and properties of pyroglutamate-modiﬁed Ab-
speciﬁc antibodies produced in rabbits. J Neuroimmunol 213:39–
46
2. Arendt T, Bigl V, Tennstedt A, Arendt A (1985) Neuronal loss in
different parts of the nucleus basalis is related to neuritic plaque
formation in cortical target areas in Alzheimer’s disease. Neu-
roscience 14:1–14
3. Bachtell RK, Weitemier AZ, Galvan-Rosas A et al (2003) The
Edinger–Westphal-lateral septum urocortin pathway and its
relationship to alcohol consumption. J Neurosci 23:2477–2487
4. Berridge CW, Waterhouse BD (2003) The locus coeruleus-
noradrenergic system: modulation of behavioral state and state-
dependent cognitive processes. Brain Res Rev 42:33–84
5. Bondareff W, Mountjoy CQ, Rossor RM, Iversen LL, Reynolds
GP, Hauser DL (1987) Neuronal degeneration in the locus coe-
ruleus and cortical correlates of Alzheimer’s disease. Alzheimer
Dis Assoc Disord 1:256–262
6. Busch C, Bohl J, Ohm TG (1997) Spatial, temporal and numeric
analysis of Alzheimer changes in the nucleus coeruleus. Neuro-
biol Aging 18:401–406
7. Casas C, Sergeant N, Itier JM et al (2004) Massive CA1/2 neu-
ronal loss with intraneuronal and N-terminal truncated Abeta42
accumulation in a novel Alzheimer transgenic model. Am J
Pathol 165:1289–1300
8. Christensen DZ, Kraus SL, Flohr A, Cotel MC, Wirths O, Bayer
TA (2008) Transient intraneuronal Ab rather than extracellular
plaque pathology correlates with neuron loss in the frontal cortex
of APP/PS1 mice. Acta Neuropathol 116:647–655
9. Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a
disorder of cortical cholinergic innervation. Science 219:1184–
1190
10. Cullen MJ, Ling N, Foster AC, Pelleymounter MA (2001) Uro-
cortin, corticotropin-releasing factor-2 receptors and energy
balance. Endocrinology 142:992–999
11. Cynis H, Schilling S, Bodnar M et al (2006) Inhibition of glu-
taminyl cyclase alters pyroglutamate formation in mammalian
cells. Biochim Biophys Acta 1764:1618–1625
12. D’Arrigo C, Tabaton M, Perico A (2009) N-terminal truncated
pyroglutamyl beta amyloid peptide Abetapy3–42 shows a faster
aggregation kinetics than the full-length Abeta1–42. Biopolymers
91:861–873
13. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The sub-
stantia nigra of the human brain. I. Nigrosomes and the nigral
matrix, a compartmental organization based on calbindin D28K
immunohistochemistry. Brain 122:1421–1436
14. Forno LS (1978) The Locus coeruleus in Alzheimer’s disease.
J Neuropath Exp Neurol 37:614
15. Gaszner B, Jensen KO, Farkas J et al (2009) Effects of maternal
separation on dynamics of urocortin 1 and brain-derived neuro-
trophic factor in the rat non-preganglionic Edinger–Westphal
nucleus. Int J Dev Neurosci 27:439–451
16. German DC, Manaye KF, White CL III et al (1992) Disease-
speciﬁc patterns of locus coeruleus cell loss. Ann Neurol 32:667–
676
17. Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid
cascade hypothesis. Science 256:184–185
18. Hartlage-Ru ¨bsamen M, Staffa K, Waniek A et al (2009) Devel-
opmental expression and subcellular localization of glutaminyl
cyclase in mouse brain. Int J Dev Neurosci 27:825–835
19. He W, Barrow CJ (1999) The A beta 3-pyroglutamyl and 11-
pyroglutamyl peptides found in senile plaque have greater beta-
Acta Neuropathol (2010) 120:195–207 205
123sheet forming and aggregation propensities in vitro than full-
length A beta. Biochemistry 38:10871–10877
20. Heneka MT, Ramanathan M, Jacobs AH et al (2006) Locus
coeruleus degeneration promotes Alzheimer pathogenesis in
amyloid precursor protein 23 transgenic mice. J Neurosci
26:1343–1354
21. Horn AK, Eberhorn A, Ha ¨rtig W, Ardeleanu P, Messoudi A,
Bu ¨ttner-Ennever JA (2008) Perioculomotor cell groups in mon-
key and man deﬁned by their histochemical and functional
properties: reappraisal of the Edinger–Westphal nucleus. J Comp
Neurol 507:1317–1335
22. Horn AK, Schulze C, Radtke-Schuller S (2009) The Edinger–
Westphal nucleus represents different functional cell groups in
different species. Ann N Y Acad Sci 1164:45–50
23. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y
(1994) Visualization of Abeta 42(43) and Abeta 40 in senile
plaques with end-speciﬁc Abeta monoclonals: evidence that an
initially deposited species is Abeta 42(43). Neuron 13:45–53
24. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y (1995)
Amyloid beta protein (Abeta) deposition: Abeta 42(43) precedes
Abeta 40 in Down syndrome. Ann Neurol 37:294–299
25. Jackisch R, Gansser S, Cassel JC (2008) Noradrenergic dener-
vation facilitates the release of acetylcholine and serotonin in the
hippocampus: towards a mechanism underlying upregulations
described in MCI patients? Exp Neurol 213:345–353
26. Kalinin S, Gavrilyuk V, Polak P et al (2007) Noradrenaline
deﬁciency in brain increases b-amyloid plaque burden in an
animal model of Alzheimer’s disease. Neurobiol Aging 28:1206–
1214
27. Konigsmark BW (1970) Methods for the counting of neurons. In:
Nauta WHJ, Ebbesson SOE (eds) Contemporary research meth-
ods in neuroanatomy. Springer, Berlin, pp 315–380
28. Koob GF, Heinrichs SC (1999) A role of corticotropin-releasing
factor and urocortin in behavioral responses to stressors. Brain
Res 848:141–152
29. Liu K, Solano I, Mann D et al (2006) Characterization of Abe-
ta11–40/42 peptide deposition in Alzheimer’s disease and young
Down’s syndrome brains: implication of N-terminally truncated
Abeta species in the pathogenesis of Alzheimer’s disease. Acta
Neuropathol 112:163–174
30. Loy R, Koziell DA, Lindsay JD, Moore RY (1980) Noradrenergic
innervation of the adult rat hippocampal formation. J Comp
Neurol 189:699–710
31. Mai JK, Assheuer J, Paxinos G (2004) Atlas of the human brain.
Academic Press, San Diego
32. Mann DM, Yates PO, Marcyniuk B (1984) Monoaminergic
neurotransmitter systems in presenile Alzheimer’s disease and
in senile dementia of Alzheimer type. Clin Neuropathol 3:199–
205
33. Marcyniuk NB, Mann DM, Yates PO (1986) The topography of
cell loss from locus coeruleus in Alzheimer’s disease. J Neurol
Sci 76:335–345
34. Marcyniuk NB, Mann DM, Yates PO (1986) Loss of nerve cells
from locus coeruleus in Alzheimer’s disease is topographically
arranged. Neurosci Lett 64:247–252
35. Marino MD, Bourdelat-Parks BN, Weinshenker D (2005) Genetic
reduction of noradrenergic function alters social memory and
reduces aggression in mice. Behav Brain Res 161:197–208
36. McColl G, Roberts BR, Gunn AP et al (2009) The Caenorhabditis
elegans Ab1-42 model of Alzheimer’s disease predominantly
expresses Ab3-42. J Biol Chem 284:22697–22702
37. McKhann G, Drachmann D, Folstein M, Katzman R, Price D,
Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease:
report of the NINCDS-ADRDA work group under the auspices of
Department of Health and Human Services Task Force on Alz-
heimer’s disease. Neurology 34:939–944
38. Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R
(2005) Amino-terminally truncated Abeta peptide species are the
main component of cotton wool plaques. Biochemistry
44:10810–10821
39. Moreau JL, Kilpatrick G, Jenck F (1997) Urocortin, a novel
neuropeptide with anxiogenic-like properties. Neuroreport 8:1697–
1701
40. Muresan Z, Muresan V (2008) Seeding neuritic plaques from the
distance: a possible role for brainstem neurons in the develop-
ment of Alzheimer’s disease. Neurodegener Dis 5:250–253
41. Paxinos G, Huang XF, Toga AW (2000) The rhesus monkey
brain in stereotaxic coordinates. Academic Press, San Diego
42. Paxinos G, Huang XF (1995) Atlas of the human brainstem.
Academic Press, San Diego
43. Piccini A, Russo C, Gliozzi A et al (2005) Beta-amyloid is dif-
ferent in normal aging and in Alzheimer’s disease. J Biol Chem
280:34186–34192
44. Roßner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V (1998)
The regulation of amyloid precursor protein metabolism by
cholinergic mechanisms and neurotrophin receptor signaling.
Prog Neurobiol 56:541–569
45. Ru ¨b U, Del Tredici K, Schultz C, Bu ¨ttner-Ennever JA, Braak H
(2001) The premotor region essential for rapid vertical eye
movements shows early involvement in Alzheimer’s disease-
related cytoskeletal pathology. Vision Res 41:2149–2156
46. Russo C, Schettini G, Saido TC et al (2000) Presenilin-1 muta-
tions in Alzheimer’s disease. Nature 405:531–532
47. Russo C, Violani E, Salis S et al (2002) Pyroglutamate-modiﬁed
amyloid beta-peptides–AbetaN3(pE)–strongly affect cultured
neuron and astrocyte survival. J Neurochem 82:1480–1489
48. Ryabinin AE, Tsivkovskaia NO, Ryabinin SA (2005) Urocortin
1-containing neurons in the human Edinger–Westphal nucleus.
Neuroscience 134:1317–1323
49. Saido TC (1998) Alzheimer’s disease as proteolytic disorders:
anabolism and catabolism of beta-amyloid. Neurobiol Aging
19:S69–S75
50. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawa-
shima S (1995) Dominant and differential deposition of distinct
beta-amyloid peptide species, Abeta N3(pE), in senile plaques.
Neuron 14:457–466
51. Saido TC, Yamao H, Iwatsubo T, Kawashima S (1996) Amino-
and carboxyl-terminal heterogeneity of beta-amyloid peptides
deposited in human brain. Neurosci Lett 215:173–176
52. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU
(2004) Glutaminyl cyclases unfold glutamyl cyclase activity
under mild acid conditions. FEBS Lett 563:191–196
53. Schilling S, Lauber T, Schaupp M et al (2006) On the seeding and
oligomerization of pGlu-amyloid peptides (in vitro). Biochemis-
try 45:12393–12399
54. Schilling S, Zeitschel U, Hoffmann T et al (2008) Glutaminyl
cyclase inhibition attenuates pyroglutamate Abeta and Alzhei-
mer’s disease-like pathology. Nat Med 14:1106–1111
55. Schilling S, Appl T, Hoffmann T et al (2008) Inhibition of glu-
taminyl cyclase prevents pGlu-Ab formation after intracortical/
hippocampal microinjection in vivo/in situ. J Neurochem
106:1225–1236
56. Schlenzig D, Manhart S, Cinar Y et al (2009) Pyroglutamate
formation inﬂuences solubility and amyloidogenicity of amyloid
peptides. Biochemistry 48:7072–7078
57. Scinto LF, Daffner KR, Dressler D et al (1994) A potential
noninvasive neurobiological test for Alzheimer’s disease. Science
266:1051–1054
58. Scinto LF, Wu CK, Firla KM, Daffner KR, Saroff D, Geula C
(1999) Focal pathology in Edinger–Westphal nucleus explains
pupillary hypersensitivity in Alzheimer’s disease. Acta Neuro-
pathol 97:557–564
206 Acta Neuropathol (2010) 120:195–207
12359. Scinto LF, Frosch M, Wu CK, Daffner KR, Gedi N, Geula C
(2001) Selective cell loss in Edinger–Westphal in asymptotic
elders and Alzheimer’s patients. Neurobiol Aging 22:729–736
60. Selkoe DJ, Schenk D (2003) Alzheimer’s disease: molecular
understanding predicts amyloid based therapeutics. Annu Rev
Pharmacol Toxicol 43:545–584
61. Sergeant N, Bombois S, Ghestem A et al (2003) Truncated beta-
amyloid peptide species in pre-clinical Alzheimer’s disease as
new targets for the vaccination approach. J Neurochem 85:1581–
1591
62. Shin RW, Ogino K, Kondo A et al (1997) Amyloid beta-protein
(Abeta) 1–40 but not Abeta1-42 contributes to the experimental
formation of Alzheimer disease amyloid ﬁbrils in rat brain.
J Neurosci 17:8187–8193
63. Spina M, Merlo-Pich E, Chan RK et al (1996) Appetite-
suppressing effects of urocortin, a CRF-related neuropeptide.
Science 273:1561–1564
64. Vanderstichele H, De Meyer G, Andreasen N et al (2005) Amino-
truncated {beta}-amyloid42 peptides in cerebrospinal ﬂuid and
prediction of progression of mild cognitive impairment. Clin
Chem 51:1650–1660
65. Vaughan J, Donaldson C, Bittencourt J et al (1995) Urocortin,
a mammalian neuropeptide related to ﬁsh urotensin I and to
corticotropin-releasing factor. Nature 378:287–292
66. Vida I, Halasy K, Szinyei C, Somogyi P, Buhl EH (1998) Unitary
IPSPs evoked by interneurons at the stratum radiatum-stratum
lacunosum-moleculare border in the CA1 area of the rat hippo-
campus in vitro. J Physiol 506:755–773
67. Weinshenker D (2008) Functional consequences of locus coeru-
leus degeneration in Alzheimer’s disease. Curr Alzheimer Res
5:342–345
68. Weitemier AZ, Tsivkovskaia NO, Ryabinin AE (2005) Urocortin
1 distribution in mouse brain is strain-dependent. Neuroscience
132:729–740
69. Weninger SC, Peters LL, Majzoub JA (2000) Urocortin expres-
sion in the Edinger–Westphal nucleus is up-regulated by stress
and corticotropin-releasing hormone deﬁciency. Endocrinology
141:256–263
70. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR
(1981) Alzheimer’s disease: evidence for selective loss of cho-
linergic neurons in the nucleus basalis. Ann Neurol 10:122–126
71. Wilcock GK, Esiri MM, Bowen DM, Hughes AO (1988) The
different involvement of subcortical nuclei in senile dementia of
Alzheimer’s type. J Neurol Neurosurg Psychiatry 51:842–849
72. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer
TA (2009) Intraneuronal pyroglutamate-Abeta 3–42 triggers
neurodegeneration and lethal neurological deﬁcits in a transgenic
mouse model. Acta Neuropathol 118:487–496
73. Wirths O, Bethge T, Marcello A et al (2010) Pyroglutamate
Abeta pathology in APP/PS1KI mice, sporadic and familial
Alzheimer’s disease. J Neural Transm 117:85–96
Acta Neuropathol (2010) 120:195–207 207
123